

MINUTES OF THE PHARMACEUTICAL MANAGEMENT AGENCY (PHARMAC)

BOARD MEETING JULY 2019

The meeting was held at Level 9, 40 Mercer Street, Wellington, starting at 10.10am with the following attendees:

Board members

Steve Maharey	Chair
Jan White	Deputy Chair
Ross Lawrenson	Board Member
Jens Mueller	Board Member
David Lui	Observer, CAC Chair
Mark Weatherall	Observer, PTAC Chair
Peter Bramley	Observer, DHB Representative

PHARMAC staff in attendance

Sarah Fitt	Chief Executive
Lisa Williams	Director of Operations
Alison Hill	Director of Engagement & Implementation
Michael Johnson	Director of Strategic Initiatives
Mark Woodard	Director of Corporate Services/CFO
Lizzy Cohen	Board Secretary

Adrienne Martin, Andrew Davies, Fiona Rutherford, Rachel Read, Rob Turner and Jannel Fisher (PHARMAC staff) attended for relevant items.

Professor Stephen Munn presented to the Board on medical devices 10.45am – 11.30am.

1. Directors' Only Discussion

2. Apologies

Nicole Anderson, Board Member

3. Record of Previous Board and Committee Meetings

3.1 Minutes of June 2019 Board Meeting

resolved to adopt the minutes of the June 2019 meeting as being a true and correct record.

Jens Mueller and Ross Lawrenson (carried)

3.2 Minutes of June 2019 Audit and Forecast Committee Meeting

noted the minutes of the June Audit and Forecast Committee meeting.

3.3 Summary of May 2019 PTAC Meeting Minutes

noted the following summary of the record of the Pharmacology and Therapeutics Advisory Committee (PTAC) meeting held on 23 and 24 May 2019; and

noted the minutes for the May PTAC meeting will be published on the PHARMAC website by 5 August 2019

3.4 Consumer Advisory Committee (CAC) Recommendations – June 2019

noted the recommendations of the Consumer Advisory Committee and the proposed/completed actions by PHARMAC staff.

4. Interests Register

noted the interests register; and

noted any decisions by the Chair to manage actual or potential conflicts of interest, as follows:

[None required]

5. Matters Arising

noted the matter's arising.

6. Chairman's Report

6.1 Verbal Report

noted the Chair's verbal report.

10.45am Professor Stephen Munn presentation on medical devices.

12.04pm continued with Board meeting

6.2 Correspondence

noted the correspondence report.

7. Chief Executive's Report

noted the Chief Executives Report.

noted the supplementary Board paper from the Chief Executive on the PHARMAC and Accident Compensation Corporation (ACC) relationship.

8. Key Items

8.1 Pharmaceutical Budget Management Update

noted the contents of this paper.

9. Schedule and Funding

9.1 Pharmaceutical Transaction and Investment Report

noted the contents of this paper.

9.2 Medical Devices Transaction and Investment Report

noted the contents of this paper.

10. Strategic Planning and Policy

10.1 Fairer Access to Medical Devices – Next Steps

noted the level of response to PHARMAC's consultation on *Fairer Access to Medical Devices*; the next steps for this work; and the Board's role in this.

10.2 PHARMAC's Sustainable Procurement Approach

noted that PHARMAC's approach to sustainability will focus on activities aimed at improving environmentally sustainable procurement;

noted that PHARMAC has limited ability to reduce carbon emissions in New Zealand and that this will not be a key focus area;

noted the actions that PHARMAC intends to undertake to strengthen its sustainable procurement will be achieved within existing staff resource; and

noted that in some cases there are potential financial trade-offs to be made to procure more sustainable pharmaceutical options.

10.3 Update on the work programme to increase public trust and confidence in PHARMAC

noted the activities underway to increase public trust and confidence in PHARMAC and to make our processes faster, clearer and simpler; and

noted that the Minister of Health has asked PHARMAC to report to him on this work within quarter one of this financial year, and that the contents of this paper will form the basis of this report.

11. Regular Reports and Noting Papers

11.1 Communications Report

noted the content of the Communications Report covering June 2019.

11.2 Risk report and Register

noted the updated risk register.

11.3 Summary of Decisions Made Under Delegated Authority – June 2019

noted the monthly summary of decisions made under Delegated Authority by the Chief Executive, Director of Operations, Manager Pharmaceutical Funding, Senior Advisor/Team Leader and Senior Therapeutic Group Managers/Team Leaders.

12. Interest Articles

13. General Business

Date of Next Meeting

The date for the next Board meeting is set for Friday 27 September 2019 in Wellington, commencing with the Directors only from 9.00am, and attendees and relevant staff from 9.30am.

The meeting closed at 1.26pm.

Chair:

Date: